Jiang, Y;
Zhou, X;
Ip, FC;
Chan, P;
Chen, Y;
Lai, NCH;
Cheung, K;
... Ip, NY; + view all
(2022)
Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.
Alzheimer's & Dementia
, 18
(1)
pp. 88-102.
10.1002/alz.12369.
Preview |
Text
Hardy_Alzheimer s Dementia - 2021 - Jiang - Large‐scale plasma proteomic profiling identifies a high‐performance biomarker.pdf Download (4MB) | Preview |
Abstract
INTRODUCTION: Blood proteins are emerging as candidate biomarkers for Alzheimer's disease (AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers and develop a high-performance, blood-based test for AD. METHODS: We quantified 1160 plasma proteins in a Hong Kong Chinese cohort by high-throughput proximity extension assay and validated the results in an independent cohort. In subgroup analyses, plasma biomarkers for amyloid, tau, phosphorylated tau, and neurodegeneration were used as endophenotypes of AD. RESULTS: We identified 429 proteins that were dysregulated in AD plasma. We selected 19 “hub proteins” representative of the AD plasma protein profile, which formed the basis of a scoring system that accurately classified clinical AD (area under the curve = 0.9690–0.9816) and associated endophenotypes. Moreover, specific hub proteins exhibit disease stage-dependent dysregulation, which can delineate AD stages. DISCUSSION: This study comprehensively profiled the AD plasma proteome and serves as a foundation for a high-performance, blood-based test for clinical AD screening and staging.
| Type: | Article |
|---|---|
| Title: | Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/alz.12369 |
| Publisher version: | https://doi.org/10.1002/alz.12369 |
| Language: | English |
| Additional information: | Copyright © 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Alzheimer’s disease, biomarker panel, diagnosis, disease staging, neurodegenerative disease, plasma proteome, prognosis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10129542 |
Archive Staff Only
 |
View Item |
